Medable is a U.S. provider of patient software platforms that enable clinical leaders to adopt patient-centered research strategies. Launched the new TeleVisit mobile app co-developed and deployed with PPD, as well as the TeleConsent™ and TeleCOA™ apps, all of which use web and mobile technologies to virtually connect patients to sites and sponsors. The new app enables patients to obtain clinical advice, obtain informed and re-consent, and share outcome assessments from the comfort of a patient’s home around the world. Recently, Medable received $78 million in Series C+ financing.
This article is reproduced from: https://www.itjuzi.com/investevent/13374560
This site is for inclusion only, and the copyright belongs to the original author.